It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Members of the Herpesviridae, including the medically important alphaherpesvirus varicella-zoster virus (VZV), induce fusion of the virion envelope with cell membranes during entry, and between cells to form polykaryocytes in infected tissues. The conserved glycoproteins, gB, gH and gL, are the core functional proteins of the herpesvirus fusion complex. gB serves as the primary fusogen via its fusion loops, but functions for the remaining gB domains remain unexplained. As a pathway for biological discovery of domain function, our approach used structure-based analysis of the viral fusogen together with a neutralizing antibody. We report here a 2.8 Å cryogenic-electron microscopy structure of native gB recovered from VZV-infected cells, in complex with a human monoclonal antibody, 93k. This high-resolution structure guided targeted mutagenesis at the gB-93k interface, providing compelling evidence that a domain spatially distant from the gB fusion loops is critical for herpesvirus fusion, revealing a potential new target for antiviral therapies.
Herpesvirus virions have an outer lipid membrane dotted with glycoproteins that enable fusion with cell membranes to initiate entry and establish infection. Here the authors elucidate the structural mechanism of a neutralizing antibody derived from a patient infected by the herpesvirus varicella-zoster virus and targeted to its fusogen, glycoprotein-B.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Stanford University School of Medicine, Department of Pediatrics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
2 GSK Vaccines, Cambridge, USA (GRID:grid.168010.e); Syros Pharmaceuticals, Inc. Cambridge, USA (GRID:grid.168010.e)
3 Structural Biology, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
4 Institute of Molecular Biology & Genetics, Seoul National University, Department of Biological Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
5 Bioengineering, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
6 GSK Vaccines, Cambridge, USA (GRID:grid.168010.e); Moderna, Cambridge, USA (GRID:grid.479574.c) (ISNI:0000 0004 1791 3172)
7 Bioengineering, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Division of Cryo-EM and Bioimaging SSRL, SLAC National Accelerator Laboratory, Menlo Park, USA (GRID:grid.445003.6) (ISNI:0000 0001 0725 7771)
8 Stanford University School of Medicine, Department of Pediatrics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)